

Rev03
Update: Dec,14,2021

DATASHEET

Exodus-2/CCL21, Human

Cat. No.: Z02843

Product Introduction

Species	Human
Protein Construction	CCL21 (Ser24-Pro134) Accession # O00585
Purity	> 97% as analyzed by SDS-PAGE > 97% as analyzed by HPLC
Endotoxin Level	< 1 EU/ μ g of protein by LAL method
Biological Activity	Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human lymphocytes is in a concentration range of 10.0-100.0 ng/ml.
Expression System	E. coli
Theoretical Molecular Weight	12.2 kDa
Formulation	Lyophilized from a 0.2 μ m filtered solution in 20 mM PB, pH 7.4, 150 mM NaCl.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

Background

Target Background : Exodus-2/CCL21 is a novel CC chemokine discovered independently by three groups from the EST database, and shows 21-33% identity to other CC chemokines. Exodus-2 contains the four conserved cysteines characteristic of β chemokines plus two additional cysteines in its unusually long carboxyl terminal domain. It is expressed in lymph nodes of certain endothelial cells, and in the spleen and appendix. Exodus-2 chemoattracts T and B lymphocytes and inhibits hematopoiesis.

Synonyms : 6Ckine; CKb9; ECL; SCYA21; SLC; TCA4; C-C motif chemokine ligand 21

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.